Advertisement
Advertisement

MDGL

MDGL logo

Madrigal Pharmaceuticals, Inc. Common Stock

545.53
USD
Sponsored
-4.72
-0.86%
Jul 16, 15:59 UTC -4
Closed
exchange

Pre-Market

539.00

-6.53
-1.20%

MDGL Earnings Reports

Positive Surprise Ratio

MDGL beat 23 of 42 last estimates.

55%

Next Report

Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$357.14M
/
-$2.62
Implied change from Q1 26 (Revenue/ EPS)
+14.71%
/
-19.38%
Implied change from Q2 25 (Revenue/ EPS)
+67.83%
/
+37.89%

Madrigal Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On May 06, 2026, MDGL reported earnings of -3.25 USD per share (EPS) for Q1 26, beating the estimate of -4.10 USD, resulting in a 20.92% surprise. Revenue reached 311.34 million, compared to an expected 306.78 million, with a 1.49% difference. The market reacted with a +7.42% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -2.62 USD, with revenue projected to reach 357.14 million USD, implying an decrease of -19.38% EPS, and increase of 14.71% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Galmed Pharmaceuticals Ltd.
Report Date
Jul 08, 2026 For Q1 26
Estimate
-$0.38
Actual
$0.28
Surprise
+174.82%
FAQ
For Q1 2026, Madrigal Pharmaceuticals, Inc. Common Stock reported EPS of -$3.25, beating estimates by 20.92%, and revenue of $311.34M, 1.49% above expectations.
The stock price moved up 7.42%, changed from $502.47 before the earnings release to $539.73 the day after.
The next earning report is scheduled for Aug 11, 2026.
Based on 13 analysts, Madrigal Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$2.62 and revenue of $357.14M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement